BRAF and colorectal carcinoma: A Swedish study previously suggested that the percentage of MSI alteration in early stage BRAF-mutated CRC might reach 50%, but in this case the presence of MSI as a positive prognostic factor overcame the negative prognosis conferred by BRAF mutation [16], meaning that most patients with left-sided BRAF-mutated tumors and MSI may not develop metastases.